Markets:

Overview

News

Currencies

International

Treasuries

Charles River Laboratories International, Inc. Common Stock (NY:CRL)

184.03 -0.01 (-0.01%)

Streaming Delayed Price Updated: 3:19 PM EST, Dec 5, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Charles River Laboratories International, Inc. Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

18 19 Next >

Wall Street Rebounds, JPMorgan Jumps On Strong Q1 Earnings: What's Driving Markets Friday? ↗

April 11, 2025

Wall Street bounced back from early losses, driven by upbeat bank earnings and cooler inflation data, while shrugging off trade war concerns.

Via Benzinga

Topics Economy World Trade

FDA’s Intent To Phase Out Animal Testing Requirement Weighs Down Charles River Stock: Retail’s Disheartened ↗

April 11, 2025

JPMorgan, which holds a ‘Neutral’ rating on the stock, opined that Charles River could see disruption from customers reassessing its preclinical strategies in the near term.

Via Stocktwits

Topics Animal Testing

What's Going On With Charles River, Certara, Simulations Plus Stocks On Friday? ↗

April 11, 2025

FDA introduces a new roadmap to reduce animal testing in monoclonal antibody development using AI models, organoid testing and real-world data to enhance safety and efficiency.

Via Benzinga

Topics Animal Testing Artificial Intelligence

These S&P500 stocks that are showing activity before the opening bell on Friday. ↗

April 11, 2025

The US market is yet to commence its session on Friday, but let's get a preview of the pre-market session and explore the top S&P500 gainers and losers driving the early market movements.

Via Chartmill

Charles River Stock: A Deep Dive Into Analyst Perspectives (11 Ratings) ↗

April 09, 2025

Via Benzinga

Tuesday's session: top gainers and losers in the S&P500 index ↗

April 08, 2025

Let's have a look at the top S&P500 gainers and losers one hour before the close of the markets of today's session.

Via Chartmill

What's going on in today's session: S&P500 movers ↗

March 31, 2025

Let's have a look at the top S&P500 gainers and losers one hour before the close of the markets of today's session.

Via Chartmill

Exploring the top movers within the S&P500 index during today's session. ↗

March 31, 2025

Wondering what's happening in today's session for the S&P500 index? Stay informed with the top movers within the S&P500 index on Monday.

Via Chartmill

What's going on in today's session: S&P500 gap up and gap down stocks ↗

March 31, 2025

Curious about the market action on Monday? Dive into the US markets to explore the gap up and gap down stocks in the S&P500 index during today's session.

Via Chartmill

Charles River and Valo Health Identify a Potential Therapeutic for Lupus Using Logica®, an AI-Powered Drug Discovery Platform

March 25, 2025

From Charles River Laboratories International, Inc.

Via Business Wire

Demystifying Charles River: Insights From 10 Analyst Reviews ↗

March 21, 2025

Via Benzinga

This FedEx Analyst Turns Bearish; Here Are Top 5 Downgrades For Friday ↗

March 21, 2025

Via Benzinga

Drug Development Inputs & Services Stocks Q4 In Review: Medpace (NASDAQ:MEDP) Vs Peers

March 21, 2025

Wrapping up Q4 earnings, we look at the numbers and key takeaways for the drug development inputs & services stocks, including Medpace (NASDAQ:MEDP) and its peers.

Via StockStory

Exploring the top movers within the S&P500 index during today's session. ↗

March 20, 2025

Curious about the S&P500 stocks that are in motion on Thursday? Join us as we explore the top movers within the S&P500 index during today's session.

Via Chartmill

Top S&P500 movers in Thursday's session ↗

March 20, 2025

Let's have a look at what is happening on the US markets in the middle of the day on Thursday. Below you can find the top S&P500 gainers and losers in today's session.

Via Chartmill

Which S&P500 stocks are gapping on Thursday? ↗

March 20, 2025

Let's have a look at the S&P500 gap up and gap down stocks in today's session.

Via Chartmill

3 Reasons CRL is Risky and 1 Stock to Buy Instead

March 20, 2025

Over the last six months, Charles River Laboratories’s shares have sunk to $173.44, producing a disappointing 15.7% loss while the S&P 500 was flat. This might have investors contemplating their next...

Via StockStory

Topics Stocks

Unpacking Q4 Earnings: UFP Technologies (NASDAQ:UFPT) In The Context Of Other Drug Development Inputs & Services Stocks

March 13, 2025

As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q4. Today, we are looking at drug development inputs & services stocks,...

Via StockStory

Charles River Laboratories to Present at Barclays Global Healthcare Conference

March 11, 2025

From Charles River Laboratories International, Inc.

Via Business Wire

Spotting Winners: Charles River Laboratories (NYSE:CRL) And Drug Development Inputs & Services Stocks In Q4

March 05, 2025

Looking back on drug development inputs & services stocks’ Q4 earnings, we examine this quarter’s best and worst performers, including Charles River Laboratories (NYSE:CRL) and its peers.

Via StockStory

Charles River Announces Agreement with Singapore General Hospital

February 25, 2025

From Charles River Laboratories International, Inc.

Via Business Wire

Uncover the latest developments among S&P500 stocks in today's session. ↗

February 24, 2025

Let's have a look at what is happening on the US markets one hour before the close of the markets on Monday. Below you can find the top S&P500 gainers and losers in today's session.

Via Chartmill

Exploring the top movers within the S&P500 index during today's session. ↗

February 24, 2025

Let's have a look at the top S&P500 gainers and losers in the middle of the day of today's session.

Via Chartmill

UFP Technologies (UFPT) Reports Q4: Everything You Need To Know Ahead Of Earnings

February 24, 2025

Medical products company UFP Technologies (NASDAQ:UFPT) will be announcing earnings results tomorrow morning. Here’s what to look for.

Via StockStory

Analyst Sees Charles River As Preclinical Leader But Maintains Neutral Stance ↗

February 19, 2025

Charles River's Q4 revenue topped estimates despite a 1.1% decline. The company forecasts a revenue drop in 2025, with biotech demand expected to stabilize.

Via Benzinga

Which S&P500 stocks are moving on Wednesday? ↗

February 19, 2025

Let's delve into the developments on the US markets one hour before the close of the markets on Wednesday. Below, you'll find the top gainers and losers within the S&P500 index during today's session.

Via Chartmill

In today's session, there are S&P500 stocks with remarkable trading volume. ↗

February 19, 2025

Curious about which S&P500 stocks are generating unusual volume on Wednesday? Find out below.

Via Chartmill

What's going on in today's session: S&P500 movers ↗

February 19, 2025

Stay informed about the performance of the S&P500 index in the middle of the day on Wednesday. Uncover the top gainers and losers in today's session for valuable insights.

Via Chartmill

Earnings To Watch: Repligen (RGEN) Reports Q4 Results Tomorrow

February 19, 2025

Biopharma manufacturing company Repligen Corporation (NASDAQ:RGEN) will be announcing earnings results tomorrow morning. Here’s what you need to know.

Via StockStory

Charles River Laboratories (NYSE:CRL) Posts Better-Than-Expected Sales In Q4

February 19, 2025

Lab services company Charles River Laboratories (NYSE:CRL) reported Q4 CY2024 results exceeding the market’s revenue expectations, but sales fell by 1.1% year on year to $1.00 billion. Its non-GAAP...

Via StockStory

< Previous 1 2 3 4 5 6 7 8 9

...

18 19 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Charles River Laboratories International, Inc. Common Stock (NY:CRL)

All News about Charles River Laboratories International, Inc. Common Stock

Starting at $3.75/week.

Subscribe Today